|
|
|
14.04.26 - 01:57
|
Biden FDA Knew About COVID Vaccine Stroke Risk And Kept Americans In The Dark (ZeroHedge)
|
|
|
Biden FDA Knew About COVID Vaccine Stroke Risk And Kept Americans In The Dark
Senate investigators spent months reviewing roughly 2,000 pages of federal records. What they found is damning. FDA and CDC officials under the Biden administration identified a significant stroke risk tied to Pfizer's COVID-19 bivalent booster in seniors - and never breathed a word to the public.
Sen. Ron Johnson (R-WI), chairman of the Senate's Permanent Subcommittee on Investigations, sent a formal letter to HHS Secretary Robert F. Kennedy Jr. laying out the evidence. He wasn't speculating. He was citing the government's own files.
"HHS records show that as early as October 2022, federal health officials identified a potential connection between the Pfizer-BioNTech COVID-19 bivalent booster and ischemic stroke for individuals over the age of 65," Johnson wrote.
An ischemic stroke means a blockage of blood to the brain. Between November 2022 and March 2023, seven separate analyses of incoming data fla...
|
|
|
|
|
13.04.26 - 13:33
|
Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors (Business Wire)
|
|
|
Mr. Epstein brings more than 30 years of global drug development and commercialization experience to support Frontier's next phase of growth as it continues to advance its pipeline of covalent precision medicines
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the appointment of David R. Epstein to its board of directors. Mr. Epstein currently serves as chairman and chief executive officer of Ottimo Pharma and was most recently chief executive officer of Seagen, where he led the company through a period of significant growth and innovation, culminating in its acquisition by Pfizer in 2023.
“David is a transformative leader with an exceptional track record of building and scaling innovative biopharmaceutical organizations,” said Chris Varma, Ph.D., co-founder, chairman, ...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04.26 - 08:18
|
Pfizer Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer mit einem Kursziel von 30 US-Dollar auf "Neutral" belassen. Chris Schott sieht für die Ziele des Pharmaherstellers Luft nach oben, wie er am Donnerstag in seinem Ausblick ......
|
|
|
09.04.26 - 16:06
|
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT.
Shareholders can find information on accessing and registering for the virtual meeting at https://meetnow.global/PFE2026. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either the control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live meeting. No control number is required to participate in a listen-only mode.
Registered and most beneficial shareholders can vote during the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform. Some benefici...
|
|
|
|
|
|
|
|
|
06.04.26 - 18:18
|
High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout (24/7 Wall St.)
|
|
|
Pharmaceutical companies AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories. AbbVie is riding a post-Humira reinvention, while Pfizer is still unwinding its COVID-era identity and searching for a durable growth engine. For dividend investors, the contrast is sharp. Skyrizi Carries AbbVie. Pfizer's Non-COVID Portfolio Carries ... High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
